Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
US12054538B2 · kind B2 · utility
0Cited by
12References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 13, 2022 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Oct 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16111
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.